330 related articles for article (PubMed ID: 24070414)
1. Health economic evaluation of vaccination strategies for the prevention of herpes zoster and postherpetic neuralgia in Germany.
Ultsch B; Weidemann F; Reinhold T; Siedler A; Krause G; Wichmann O
BMC Health Serv Res; 2013 Sep; 13():359. PubMed ID: 24070414
[TBL] [Abstract][Full Text] [Related]
2. Health economic evaluation of a vaccine for the prevention of herpes zoster (shingles) and post-herpetic neuralgia in adults in Belgium.
Annemans L; Bresse X; Gobbo C; Papageorgiou M
J Med Econ; 2010; 13(3):537-51. PubMed ID: 20707768
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of the cost-effectiveness in the United States of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults.
Pellissier JM; Brisson M; Levin MJ
Vaccine; 2007 Nov; 25(49):8326-37. PubMed ID: 17980938
[TBL] [Abstract][Full Text] [Related]
4. Cost effectiveness of herpes zoster vaccine in Canada.
Najafzadeh M; Marra CA; Galanis E; Patrick DM
Pharmacoeconomics; 2009; 27(12):991-1004. PubMed ID: 19908924
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness analysis of a vaccination program for the prevention of herpes zoster and post-herpetic neuralgia in adults aged 50 and over in Germany.
Préaud E; Uhart M; Böhm K; Aidelsburger P; Anger D; Bianic F; Largeron N
Hum Vaccin Immunother; 2015; 11(4):884-96. PubMed ID: 25933182
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness of varicella vaccine against herpes zoster and post-herpetic neuralgia for elderly in Japan.
Hoshi SL; Kondo M; Okubo I
Vaccine; 2017 May; 35(24):3264-3271. PubMed ID: 28479176
[TBL] [Abstract][Full Text] [Related]
7. The potential cost-effectiveness of vaccination against herpes zoster and post-herpetic neuralgia.
Brisson M; Pellissier JM; Camden S; Quach C; De Wals P
Hum Vaccin; 2008; 4(3):238-45. PubMed ID: 18382137
[TBL] [Abstract][Full Text] [Related]
8. Herpes zoster vaccine: A health economic evaluation for Switzerland.
Blank PR; Ademi Z; Lu X; Szucs TD; Schwenkglenks M
Hum Vaccin Immunother; 2017 Jul; 13(7):1495-1504. PubMed ID: 28481678
[TBL] [Abstract][Full Text] [Related]
9. Cost-Effectiveness of Herpes Zoster Vaccine for Persons Aged 50 Years.
Le P; Rothberg MB
Ann Intern Med; 2015 Oct; 163(7):489-97. PubMed ID: 26344036
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness of vaccination of the elderly against herpes zoster in The Netherlands.
de Boer PT; Pouwels KB; Cox JM; Hak E; Wilschut JC; Postma MJ
Vaccine; 2013 Feb; 31(9):1276-83. PubMed ID: 23306360
[TBL] [Abstract][Full Text] [Related]
11. A systematic review of the cost effectiveness of herpes zoster vaccination.
Szucs TD; Pfeil AM
Pharmacoeconomics; 2013 Feb; 31(2):125-36. PubMed ID: 23335045
[TBL] [Abstract][Full Text] [Related]
12. Budget-Impact Analysis of Alternative Herpes Zoster Vaccine Strategies: A U.S. HMO Perspective.
Graham J; Mauskopf J; Kawai K; Johnson KD; Xu R; Acosta CJ
J Manag Care Spec Pharm; 2016 Jul; 22(7):872-88. PubMed ID: 27348287
[TBL] [Abstract][Full Text] [Related]
13. Economic evaluation of a vaccine for the prevention of herpes zoster and post-herpetic neuralgia in older adults in Switzerland.
Szucs TD; Kressig RW; Papageorgiou M; Kempf W; Michel JP; Fendl A; Bresse X
Hum Vaccin; 2011 Jul; 7(7):749-56. PubMed ID: 21606685
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness of the recombinant zoster vaccine in the German population aged ≥60 years old.
Van Oorschot D; Anastassopoulou A; Poulsen Nautrup B; Varghese L; von Krempelhuber A; Neine M; Lorenc S; Curran D
Hum Vaccin Immunother; 2019; 15(1):34-44. PubMed ID: 30130448
[TBL] [Abstract][Full Text] [Related]
15. Public Health Impact and Cost-Effectiveness of Non-live Adjuvanted Recombinant Zoster Vaccine in Canadian Adults.
McGirr A; Van Oorschot D; Widenmaier R; Stokes M; Ganz ML; Jung H; Varghese L; Curran D
Appl Health Econ Health Policy; 2019 Oct; 17(5):723-732. PubMed ID: 31250218
[TBL] [Abstract][Full Text] [Related]
16. Epidemiology and cost of herpes zoster and postherpetic neuralgia in Germany.
Ultsch B; Köster I; Reinhold T; Siedler A; Krause G; Icks A; Schubert I; Wichmann O
Eur J Health Econ; 2013 Dec; 14(6):1015-26. PubMed ID: 23271349
[TBL] [Abstract][Full Text] [Related]
17. The use of Zostavax in Spain: the economic case for vaccination of individuals aged 50 years and older.
Lopez-Belmonte JL; Cisterna R; Gil de Miguel A; Guilmet C; Bianic F; Uhart M
J Med Econ; 2016 Jun; 19(6):576-86. PubMed ID: 26808422
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness of vaccination against herpes zoster.
de Boer PT; Wilschut JC; Postma MJ
Hum Vaccin Immunother; 2014; 10(7):2048-61. PubMed ID: 25424815
[TBL] [Abstract][Full Text] [Related]
19. COST-EFFECTIVENESS ANALYSIS OF HERPES ZOSTER VACCINATION IN ITALIAN ELDERLY PERSONS.
Coretti S; Codella P; Romano F; Ruggeri M; Cicchetti A
Int J Technol Assess Health Care; 2016 Jan; 32(4):233-240. PubMed ID: 27624398
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness of Recombinant Zoster Vaccine (RZV) and Varicella Vaccine Live (VVL) against herpes zoster and post-herpetic neuralgia among adults aged 65 and over in Japan.
Hoshi SL; Seposo X; Shono A; Okubo I; Kondo M
Vaccine; 2019 Jun; 37(27):3588-3597. PubMed ID: 31153691
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
